The Safety Profiles of Adalimumab, Infliximab, Etanercept, Secukinumab and Ustekinumab in Psoriasis – A 30-month Observational Cohort Prospective Study of Adverse Events in Biologic Therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43929415" target="_blank" >RIV/00064173:_____/24:43929415 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/24:43929415 RIV/00216208:11130/24:10510272 RIV/00064165:_____/24:10510272

Výsledek na webu

<a href="https://actadermatovenerologicacroatica.hr/wp-content/uploads/2025/11/2-Paluch.pdf" target="_blank" >https://actadermatovenerologicacroatica.hr/wp-content/uploads/2025/11/2-Paluch.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

The Safety Profiles of Adalimumab, Infliximab, Etanercept, Secukinumab and Ustekinumab in Psoriasis – A 30-month Observational Cohort Prospective Study of Adverse Events in Biologic Therapy

Popis výsledku v původním jazyce

Background: Although biologic agents are very effective, long-term comparative studies demonstrating their safety relative to one another are still lacking. Methods: A total of 124 patients with psoriasis were followed up for 30 months; 74 received anti-TNF-alpha inhibitors (adalimumab, etanercept, infliximab), 33 were on ustekinumab, and 17 were treated with secukinumab. The rates of adverse events in these groups were recorded and statistically analyzed. Results: Infliximab-treated patients showed a high occurrence of asymptomatic, but increased liver enzymes, fatigue, and respiratory as well as dermatologic infections. Adalimumab-treated patients were more often affected by musculoskeletal disorders and infections of all types. Patients treated with secukinumab presented with higher rates of cardiovascular disorders as well as respiratory and dermatologic infections. The group receiving etanercept was more often diagnosed with musculoskeletal and reproductive disorders, specifically menstrual disorders. The rates of therapy discontinuation and serious adverse events did not reach statistically significant values. Conclusion: A higher incidence of adverse events was observed among adalimumab-, and infliximab-treated patients, with ustekinumab found to have the safest profile. Our results demonstrate that a personalized approach, including evaluation of a patient&apos;s risk profile, is necessary before commencing a biologic. Further research is warranted to confirm the findings of our study.

Název v anglickém jazyce

The Safety Profiles of Adalimumab, Infliximab, Etanercept, Secukinumab and Ustekinumab in Psoriasis – A 30-month Observational Cohort Prospective Study of Adverse Events in Biologic Therapy

Popis výsledku anglicky

Background: Although biologic agents are very effective, long-term comparative studies demonstrating their safety relative to one another are still lacking. Methods: A total of 124 patients with psoriasis were followed up for 30 months; 74 received anti-TNF-alpha inhibitors (adalimumab, etanercept, infliximab), 33 were on ustekinumab, and 17 were treated with secukinumab. The rates of adverse events in these groups were recorded and statistically analyzed. Results: Infliximab-treated patients showed a high occurrence of asymptomatic, but increased liver enzymes, fatigue, and respiratory as well as dermatologic infections. Adalimumab-treated patients were more often affected by musculoskeletal disorders and infections of all types. Patients treated with secukinumab presented with higher rates of cardiovascular disorders as well as respiratory and dermatologic infections. The group receiving etanercept was more often diagnosed with musculoskeletal and reproductive disorders, specifically menstrual disorders. The rates of therapy discontinuation and serious adverse events did not reach statistically significant values. Conclusion: A higher incidence of adverse events was observed among adalimumab-, and infliximab-treated patients, with ustekinumab found to have the safest profile. Our results demonstrate that a personalized approach, including evaluation of a patient&apos;s risk profile, is necessary before commencing a biologic. Further research is warranted to confirm the findings of our study.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Acta Dermatovenerologica Croatica

ISSN

1330-027X

e-ISSN

1847-6538

Svazek periodika

32

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

HR - Chorvatská republika

Počet stran výsledku

10

Strana od-do

7-16

Kód UT WoS článku

001673747900002

EID výsledku v databázi Scopus

2-s2.0-85197609078